Australia markets closed

Satellos Bioscience Inc. (MSCL.TO)

Toronto - Toronto Real-time price. Currency in CAD
Add to watchlist
0.5400-0.0400 (-6.90%)
At close: 03:49PM EDT
Full screen
Previous close0.5800
Open0.5500
Bid0.5400 x N/A
Ask0.5700 x N/A
Day's range0.5400 - 0.5500
52-week range0.2900 - 0.8000
Volume13,000
Avg. volume60,322
Market cap60.908M
Beta (5Y monthly)1.17
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est1.20
  • Business Wire

    Satellos Announces Formation of Clinical Advisory Board to Support Advancing SAT-3247 in Clinical Trial Development for Duchenne Muscular Dystrophy

    TORONTO, May 28, 2024--Satellos Bioscience Inc. ("Satellos" or the "Company") (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today the formation of a Clinical Advisory Board comprised of distinguished clinical research leaders and experts in drug development in genetic muscle disorders, including Duchenne muscular dystrophy (DMD or Duchenne).

  • Business Wire

    Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders

    TORONTO, May 14, 2024--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today the results of its Annual and Special Meeting of Shareholders held today, May 14, 2024 (the "Meeting").

  • Business Wire

    Satellos Bioscience Announces Q1 2024 Financial Results and Operational Highlights

    TORONTO, May 14, 2024--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today its financial results and operational highlights for the three months ended March 31, 2024. All references to currency in this press release are in Canadian dollars unless otherwise noted.